Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.
Identifieur interne : 000B27 ( Main/Exploration ); précédent : 000B26; suivant : 000B28Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.
Auteurs : Firas Abdollah [États-Unis] ; Zaojun Ye [États-Unis] ; David C. Miller [États-Unis] ; Susan M. Linsell [États-Unis] ; James E. Montie [États-Unis] ; James O. Peabody [États-Unis] ; Khurshid R. Ghani [États-Unis]Source :
- European urology [ 1873-7560 ] ; 2016.
Descripteurs français
- KwdFr :
- Ajustement du risque (méthodes), Amélioration de la qualité (MeSH), Antigène spécifique de la prostate (analyse), Biopsie (effets indésirables), Biopsie (méthodes), Biopsie (statistiques et données numériques), Comorbidité (MeSH), Espérance de vie (MeSH), Gestion des soins aux patients (méthodes), Grading des tumeurs (MeSH), Humains (MeSH), Mâle (MeSH), Prostate (anatomopathologie), Stadification tumorale (MeSH), Sujet âgé (MeSH), Sélection de patients (MeSH), Toucher rectal (méthodes), Toucher rectal (statistiques et données numériques), Tumeurs de la prostate (anatomopathologie), Tumeurs de la prostate (thérapie), Tumeurs de la prostate (épidémiologie), États-Unis (épidémiologie).
- MESH :
- analyse : Antigène spécifique de la prostate.
- anatomopathologie : Prostate, Tumeurs de la prostate.
- effets indésirables : Biopsie.
- méthodes : Ajustement du risque, Biopsie, Gestion des soins aux patients, Toucher rectal.
- statistiques et données numériques : Biopsie, Toucher rectal.
- thérapie : Tumeurs de la prostate.
- épidémiologie : Tumeurs de la prostate, États-Unis.
- Amélioration de la qualité, Comorbidité, Espérance de vie, Grading des tumeurs, Humains, Mâle, Stadification tumorale, Sujet âgé, Sélection de patients.
English descriptors
- KwdEn :
- Aged (MeSH), Biopsy (adverse effects), Biopsy (methods), Biopsy (statistics & numerical data), Comorbidity (MeSH), Digital Rectal Examination (methods), Digital Rectal Examination (statistics & numerical data), Humans (MeSH), Life Expectancy (MeSH), Male (MeSH), Neoplasm Grading (MeSH), Neoplasm Staging (MeSH), Patient Care Management (methods), Patient Selection (MeSH), Prostate (pathology), Prostate-Specific Antigen (analysis), Prostatic Neoplasms (epidemiology), Prostatic Neoplasms (pathology), Prostatic Neoplasms (therapy), Quality Improvement (MeSH), Risk Adjustment (methods), United States (epidemiology).
- MESH :
- chemical , analysis : Prostate-Specific Antigen.
- adverse effects : Biopsy.
- epidemiology : Prostatic Neoplasms, United States.
- methods : Biopsy, Digital Rectal Examination, Patient Care Management, Risk Adjustment.
- pathology : Prostate, Prostatic Neoplasms.
- statistics & numerical data : Biopsy, Digital Rectal Examination.
- therapy : Prostatic Neoplasms.
- Aged, Comorbidity, Humans, Life Expectancy, Male, Neoplasm Grading, Neoplasm Staging, Patient Selection, Quality Improvement.
Abstract
BACKGROUND
The potential harms of a prostate cancer (PCa) diagnosis may outweigh its benefits in elderly men.
OBJECTIVE
To assess the use of prostate biopsy in men with limited life expectancy (LE) within the practices comprising the Michigan Urological Surgery Improvement Collaborative (MUSIC).
DESIGN, SETTING, AND PARTICIPANTS
MUSIC is a consortium of 42 practices and nearly 85% of the urologists in Michigan. From July 2013 to October 2014, clinical data were collected prospectively for all men undergoing prostate biopsy.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS
We calculated comorbidity-adjusted LE in men aged ≥66 yr and identified men with <10 yr LE (limited LE) undergoing a first biopsy. Our LE calculator was not designed for men aged <66 yr; thus these men were excluded. Multivariable models estimated the proportion of all biopsies performed for men with limited LE in each MUSIC practice, adjusting for differences in patient characteristics. We also evaluated what treatments, if any, these patients received.
RESULTS AND LIMITATIONS
Among 3035 men aged ≥66 yr undergoing initial prostate biopsy, 60% had none of the measured comorbidities. Overall, 547 men (18%) had limited LE. Compared with men with a longer LE, these men had significantly higher prostate-specific antigen levels and abnormal digital rectal examination findings. The adjusted proportion of biopsies performed for men with limited LE ranged from 3.8% to 39% across MUSIC practices (p < 0.001). PCa was diagnosed in 69% of men with limited LE; among this group, 74% received any active treatment. Of these men, 46% had high-grade cancer (Gleason score 8-10).
CONCLUSIONS
Among a large and diverse group of urology practices, nearly 20% of prostate biopsies are performed in men with limited LE. These data provide useful context for quality improvement efforts aimed at optimizing patient selection for prostate biopsy.
PATIENT SUMMARY
In this report, nearly 2 of every 10 men undergoing prostate biopsy had a life expectancy (LE) <10 yr. Implementing LE calculators in clinical practice may help refine patient selection for prostate biopsy.
DOI: 10.1016/j.eururo.2016.03.054
PubMed: 27113032
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.</title><author><name sortKey="Abdollah, Firas" sort="Abdollah, Firas" uniqKey="Abdollah F" first="Firas" last="Abdollah">Firas Abdollah</name><affiliation wicri:level="2"><nlm:affiliation>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Ye, Zaojun" sort="Ye, Zaojun" uniqKey="Ye Z" first="Zaojun" last="Ye">Zaojun Ye</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Linsell, Susan M" sort="Linsell, Susan M" uniqKey="Linsell S" first="Susan M" last="Linsell">Susan M. Linsell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Peabody, James O" sort="Peabody, James O" uniqKey="Peabody J" first="James O" last="Peabody">James O. Peabody</name><affiliation wicri:level="2"><nlm:affiliation>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Ghani, Khurshid R" sort="Ghani, Khurshid R" uniqKey="Ghani K" first="Khurshid R" last="Ghani">Khurshid R. Ghani</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic address: kghani@med.umich.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27113032</idno><idno type="pmid">27113032</idno><idno type="doi">10.1016/j.eururo.2016.03.054</idno><idno type="wicri:Area/Main/Corpus">000B85</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000B85</idno><idno type="wicri:Area/Main/Curation">000B85</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000B85</idno><idno type="wicri:Area/Main/Exploration">000B85</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.</title><author><name sortKey="Abdollah, Firas" sort="Abdollah, Firas" uniqKey="Abdollah F" first="Firas" last="Abdollah">Firas Abdollah</name><affiliation wicri:level="2"><nlm:affiliation>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Ye, Zaojun" sort="Ye, Zaojun" uniqKey="Ye Z" first="Zaojun" last="Ye">Zaojun Ye</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Linsell, Susan M" sort="Linsell, Susan M" uniqKey="Linsell S" first="Susan M" last="Linsell">Susan M. Linsell</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Peabody, James O" sort="Peabody, James O" uniqKey="Peabody J" first="James O" last="Peabody">James O. Peabody</name><affiliation wicri:level="2"><nlm:affiliation>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Ghani, Khurshid R" sort="Ghani, Khurshid R" uniqKey="Ghani K" first="Khurshid R" last="Ghani">Khurshid R. Ghani</name><affiliation wicri:level="2"><nlm:affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic address: kghani@med.umich.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Urology, University of Michigan, Ann Arbor, MI</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author></analytic><series><title level="j">European urology</title><idno type="eISSN">1873-7560</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Biopsy (adverse effects)</term><term>Biopsy (methods)</term><term>Biopsy (statistics & numerical data)</term><term>Comorbidity (MeSH)</term><term>Digital Rectal Examination (methods)</term><term>Digital Rectal Examination (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Life Expectancy (MeSH)</term><term>Male (MeSH)</term><term>Neoplasm Grading (MeSH)</term><term>Neoplasm Staging (MeSH)</term><term>Patient Care Management (methods)</term><term>Patient Selection (MeSH)</term><term>Prostate (pathology)</term><term>Prostate-Specific Antigen (analysis)</term><term>Prostatic Neoplasms (epidemiology)</term><term>Prostatic Neoplasms (pathology)</term><term>Prostatic Neoplasms (therapy)</term><term>Quality Improvement (MeSH)</term><term>Risk Adjustment (methods)</term><term>United States (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Ajustement du risque (méthodes)</term><term>Amélioration de la qualité (MeSH)</term><term>Antigène spécifique de la prostate (analyse)</term><term>Biopsie (effets indésirables)</term><term>Biopsie (méthodes)</term><term>Biopsie (statistiques et données numériques)</term><term>Comorbidité (MeSH)</term><term>Espérance de vie (MeSH)</term><term>Gestion des soins aux patients (méthodes)</term><term>Grading des tumeurs (MeSH)</term><term>Humains (MeSH)</term><term>Mâle (MeSH)</term><term>Prostate (anatomopathologie)</term><term>Stadification tumorale (MeSH)</term><term>Sujet âgé (MeSH)</term><term>Sélection de patients (MeSH)</term><term>Toucher rectal (méthodes)</term><term>Toucher rectal (statistiques et données numériques)</term><term>Tumeurs de la prostate (anatomopathologie)</term><term>Tumeurs de la prostate (thérapie)</term><term>Tumeurs de la prostate (épidémiologie)</term><term>États-Unis (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Prostate-Specific Antigen</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Biopsy</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Antigène spécifique de la prostate</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Prostate</term><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Biopsie</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Prostatic Neoplasms</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Biopsy</term><term>Digital Rectal Examination</term><term>Patient Care Management</term><term>Risk Adjustment</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Ajustement du risque</term><term>Biopsie</term><term>Gestion des soins aux patients</term><term>Toucher rectal</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Prostate</term><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Biopsy</term><term>Digital Rectal Examination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Biopsie</term><term>Toucher rectal</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs de la prostate</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Tumeurs de la prostate</term><term>États-Unis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Comorbidity</term><term>Humans</term><term>Life Expectancy</term><term>Male</term><term>Neoplasm Grading</term><term>Neoplasm Staging</term><term>Patient Selection</term><term>Quality Improvement</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Amélioration de la qualité</term><term>Comorbidité</term><term>Espérance de vie</term><term>Grading des tumeurs</term><term>Humains</term><term>Mâle</term><term>Stadification tumorale</term><term>Sujet âgé</term><term>Sélection de patients</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The potential harms of a prostate cancer (PCa) diagnosis may outweigh its benefits in elderly men.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To assess the use of prostate biopsy in men with limited life expectancy (LE) within the practices comprising the Michigan Urological Surgery Improvement Collaborative (MUSIC).</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN, SETTING, AND PARTICIPANTS</b></p><p>MUSIC is a consortium of 42 practices and nearly 85% of the urologists in Michigan. From July 2013 to October 2014, clinical data were collected prospectively for all men undergoing prostate biopsy.</p></div><div type="abstract" xml:lang="en"><p><b>OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS</b></p><p>We calculated comorbidity-adjusted LE in men aged ≥66 yr and identified men with <10 yr LE (limited LE) undergoing a first biopsy. Our LE calculator was not designed for men aged <66 yr; thus these men were excluded. Multivariable models estimated the proportion of all biopsies performed for men with limited LE in each MUSIC practice, adjusting for differences in patient characteristics. We also evaluated what treatments, if any, these patients received.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS AND LIMITATIONS</b></p><p>Among 3035 men aged ≥66 yr undergoing initial prostate biopsy, 60% had none of the measured comorbidities. Overall, 547 men (18%) had limited LE. Compared with men with a longer LE, these men had significantly higher prostate-specific antigen levels and abnormal digital rectal examination findings. The adjusted proportion of biopsies performed for men with limited LE ranged from 3.8% to 39% across MUSIC practices (p < 0.001). PCa was diagnosed in 69% of men with limited LE; among this group, 74% received any active treatment. Of these men, 46% had high-grade cancer (Gleason score 8-10).</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Among a large and diverse group of urology practices, nearly 20% of prostate biopsies are performed in men with limited LE. These data provide useful context for quality improvement efforts aimed at optimizing patient selection for prostate biopsy.</p></div><div type="abstract" xml:lang="en"><p><b>PATIENT SUMMARY</b></p><p>In this report, nearly 2 of every 10 men undergoing prostate biopsy had a life expectancy (LE) <10 yr. Implementing LE calculators in clinical practice may help refine patient selection for prostate biopsy.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27113032</PMID><DateCompleted><Year>2018</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7560</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>11</Month></PubDate></JournalIssue><Title>European urology</Title><ISOAbbreviation>Eur Urol</ISOAbbreviation></Journal><ArticleTitle>Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.</ArticleTitle><Pagination><MedlinePgn>854-861</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0302-2838(16)30032-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eururo.2016.03.054</ELocationID><Abstract><AbstractText Label="BACKGROUND">The potential harms of a prostate cancer (PCa) diagnosis may outweigh its benefits in elderly men.</AbstractText><AbstractText Label="OBJECTIVE">To assess the use of prostate biopsy in men with limited life expectancy (LE) within the practices comprising the Michigan Urological Surgery Improvement Collaborative (MUSIC).</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">MUSIC is a consortium of 42 practices and nearly 85% of the urologists in Michigan. From July 2013 to October 2014, clinical data were collected prospectively for all men undergoing prostate biopsy.</AbstractText><AbstractText Label="OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS">We calculated comorbidity-adjusted LE in men aged ≥66 yr and identified men with <10 yr LE (limited LE) undergoing a first biopsy. Our LE calculator was not designed for men aged <66 yr; thus these men were excluded. Multivariable models estimated the proportion of all biopsies performed for men with limited LE in each MUSIC practice, adjusting for differences in patient characteristics. We also evaluated what treatments, if any, these patients received.</AbstractText><AbstractText Label="RESULTS AND LIMITATIONS">Among 3035 men aged ≥66 yr undergoing initial prostate biopsy, 60% had none of the measured comorbidities. Overall, 547 men (18%) had limited LE. Compared with men with a longer LE, these men had significantly higher prostate-specific antigen levels and abnormal digital rectal examination findings. The adjusted proportion of biopsies performed for men with limited LE ranged from 3.8% to 39% across MUSIC practices (p < 0.001). PCa was diagnosed in 69% of men with limited LE; among this group, 74% received any active treatment. Of these men, 46% had high-grade cancer (Gleason score 8-10).</AbstractText><AbstractText Label="CONCLUSIONS">Among a large and diverse group of urology practices, nearly 20% of prostate biopsies are performed in men with limited LE. These data provide useful context for quality improvement efforts aimed at optimizing patient selection for prostate biopsy.</AbstractText><AbstractText Label="PATIENT SUMMARY">In this report, nearly 2 of every 10 men undergoing prostate biopsy had a life expectancy (LE) <10 yr. Implementing LE calculators in clinical practice may help refine patient selection for prostate biopsy.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abdollah</LastName><ForeName>Firas</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Zaojun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>David C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linsell</LastName><ForeName>Susan M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montie</LastName><ForeName>James E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peabody</LastName><ForeName>James O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Vattikuti Urology Institute and VUI Center for Outcomes Research Analytics and Evaluation, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghani</LastName><ForeName>Khurshid R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic address: kghani@med.umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Michigan Urological Surgery Improvement Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Eur Urol</MedlineTA><NlmUniqueID>7512719</NlmUniqueID><ISSNLinking>0302-2838</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.21.77</RegistryNumber><NameOfSubstance UI="D017430">Prostate-Specific Antigen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Urol. 2017 Aug;198(2):231</RefSource><PMID Version="1">29370604</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="Y">Biopsy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051517" MajorTopicYN="N">Digital Rectal Examination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008017" MajorTopicYN="Y">Life Expectancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010346" MajorTopicYN="N">Patient Care Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011467" MajorTopicYN="N">Prostate</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017430" MajorTopicYN="N">Prostate-Specific Antigen</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="Y">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058996" MajorTopicYN="N">Quality Improvement</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020379" MajorTopicYN="N">Risk Adjustment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Life expectancy</Keyword><Keyword MajorTopicYN="Y">Prostate biopsy</Keyword><Keyword MajorTopicYN="Y">Variation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27113032</ArticleId><ArticleId IdType="pii">S0302-2838(16)30032-X</ArticleId><ArticleId IdType="doi">10.1016/j.eururo.2016.03.054</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Michigan</li></region></list><tree><country name="États-Unis"><region name="Michigan"><name sortKey="Abdollah, Firas" sort="Abdollah, Firas" uniqKey="Abdollah F" first="Firas" last="Abdollah">Firas Abdollah</name></region><name sortKey="Ghani, Khurshid R" sort="Ghani, Khurshid R" uniqKey="Ghani K" first="Khurshid R" last="Ghani">Khurshid R. Ghani</name><name sortKey="Linsell, Susan M" sort="Linsell, Susan M" uniqKey="Linsell S" first="Susan M" last="Linsell">Susan M. Linsell</name><name sortKey="Miller, David C" sort="Miller, David C" uniqKey="Miller D" first="David C" last="Miller">David C. Miller</name><name sortKey="Montie, James E" sort="Montie, James E" uniqKey="Montie J" first="James E" last="Montie">James E. Montie</name><name sortKey="Peabody, James O" sort="Peabody, James O" uniqKey="Peabody J" first="James O" last="Peabody">James O. Peabody</name><name sortKey="Ye, Zaojun" sort="Ye, Zaojun" uniqKey="Ye Z" first="Zaojun" last="Ye">Zaojun Ye</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SanteMusiqueV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B27 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B27 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SanteMusiqueV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27113032
|texte= Understanding the Use of Prostate Biopsy Among Men with Limited Life Expectancy in a Statewide Quality Improvement Collaborative.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27113032" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SanteMusiqueV1
| This area was generated with Dilib version V0.6.38. |  |